



## **MEDIA MENTIONS**

## Supreme Court Unlikely To Take Up Coreg Skinny Label Feud After Teva's \$235M Loss To GSK, Lawyer Says

November 3, 2022 | Boston

Ron Cahill was quoted in a Fierce Pharma article, "Supreme Court unlikely to take up Coreg skinny label feud after Teva's \$235M loss to GSK, lawyer says."

## **RELATED PEOPLE**



Ronald E. Cahill

Partner Boston

P 617-316-5312 F 617-316-5311 Ronald.Cahill@btlaw.com

## **RELATED PRACTICE AREAS**

Litigation